Overview

Belzutifan in Recurrent Clear Cell Ovarian Carcinoma

Status:
RECRUITING
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with ovarian cancer. The name of the study drug involved in this study is: \- Belzutifan (a type of Hypoxia-Inducible Factor-2 alpha (HIF-2a) inhibitor)
Phase:
PHASE2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Merck Sharp & Dohme LLC
Treatments:
belzutifan